Inhibition of hepatitis C virus replication by semi-synthetic derivatives of glycopeptide antibiotics

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 6, 2011, Pages 1287-1294

  Obeid, Susan ^a   Printsevskaya, Svetlana S ^b   Olsufyeva, Eugenia N ^b   Dallmeier, Kai ^a   Durantel, David ^c,d,e   Zoulim, Fabien ^c,d,e   Preobrazhenskaya, Maria N ^b   Neyts, Johan ^a   Paeshuyse, Jan ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b GAUSE INSTITUTE OF NEW ANTIBIOTICS   (Russian Federation)

^c INSERM   (France)

^d UNIVERSITÉ LYON 1   (France)

^e HOSPICES CIVILS DE LYON   (France)

Author keywords

Combination therapy; Directly acting antivirals; HCV; Resistance; Teicoplanin

Indexed keywords

2' METHYLCYTIDINE; 4' AZIDOCYTIDINE; ANTIVIRUS AGENT; LCTA 1701; LCTA 1703; LCTA 1704; LCTA 1707; LCTA 563; LCTA 877; LCTA 901; LCTA 914; LCTA 949; NESBUVIR; RECOMBINANT ALPHA2B INTERFERON; TEICOPLANIN DERIVATIVE; TELAPREVIR; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ARTICLE; BINDING AFFINITY; BOVINE VIRAL DIARRHEA; CELL VIABILITY; COMBINATION CHEMOTHERAPY; COMPETITIVE INHIBITION; CONTROLLED STUDY; DENGUE VIRUS 2; DOSE RESPONSE; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; GENOTYPE; HEPATITIS C VIRUS; IMMUNOFLUORESCENCE; NONHUMAN; QUANTITATIVE ANALYSIS; REPLICON; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRAL CLEARANCE; VIRUS REPLICATION; WILD TYPE; YELLOW FEVER FLAVIVIRUS;

EID: 79955982571     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr104     Document Type: Article

References (37)

1. Lindenbach BD, Rice CM. Flaviviridae: the viruses and their replication. In: Knipe DM, Howley PM, Griffin DE et al., eds. Fields Virology. Philadelphia: Lippincott Williams & Wilkins, 2001; 991-1041.
2. Houghton M. Discovery of the hepatitis C virus. Liver Int 2009; 29 Suppl 1: 82-8.
3. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
4. Craxi A, Licata A. Clinical trial results of peginterferons in combination with ribavirin. Semin Liver Dis 2003; 23 Suppl 1: 35-46.
5. Craxi A. PEG IFN alfa-2a vs. alfa-2b: and the winner is.. .? J Hepatol 2010; 52: 133-5.
6. Coelmont L, Kaptein S, Paeshuyse J, et al. Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors. Antimicrob Agents Chemother 2009; 53: 967-76.
7. Schinazi RF, Bassit L, Gavegnano C. HCV drug discovery aimed at viral eradication. J Viral Hepat 2010; 17: 77-90.
8. Delang L, Coelmont L, Neyts J. Antiviral therapy for hepatitis C virus: beyond the standard of care. Viruses 2010; 2: 826-66.
9. Burton JR Jr, Everson GT. HCV NS5B polymerase inhibitors. Clin Liver Dis 2009; 13: 453-65.
10. Lange CM, Sarrazin C, Zeuzem S. Specifically targeted anti-viral therapy for hepatitis C-a new era in therapy. Aliment Pharmacol Ther 2010; 32: 14-28.
11. Thompson AJ, McHutchison JG. Antiviral resistance and specifically targeted therapy for HCV (STAT-C). J Viral Hepat 2009; 16: 377-87.
12. Kieffer TL, Kwong AD, Picchio GR. Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs). J Antimicrob Chemother 2010; 65: 202-12.
13. Pea F, Brollo L, Viale P, et al. Teicoplanin therapeutic drug monitoring in critically ill patients: a retrospective study emphasizing the importance of a loading dose. J Antimicrob Chemother 2003; 51: 971-5.
14. Sancar AA, Yegenoglu S, de Vries R, et al. Vancomycin vs teicoplanin in the treatment of Gram-positive infections: a pharmacoeconomic analysis in a Turkish University Hospital. Pharm World Sci 2008; 30: 916-23.
15. Balzarini J, Pannecouque C, De Clercq E, et al. Antiretroviral activity of semisynthetic derivatives of glycopeptide antibiotics. J Med Chem 2003; 46: 2755-64.
16. Balzarini J, Keyaerts E, Vijgen L, et al. Inhibition of feline (FIPV) and human (SARS) coronavirus by semisynthetic derivatives of glycopeptide antibiotics. Antiviral Res 2006; 72: 20-33.
17. Preobrazhenskaya MN, Olsufyeva EN. Polycyclic peptide and glycopeptide antibiotics and their derivatives as inhibitors of HIV entry. Antiviral Res 2006; 71: 227-36.
18. Printsevskaya SS, Solovieva SE, Olsufyeva EN, et al. Structure-activity relationship studies of a series of antiviral and antibacterial aglycon derivatives of the glycopeptide antibiotics vancomycin, eremomycin, and dechloroeremomycin. J Med Chem 2005; 48: 3885-90.
19. Paeshuyse J, Vliegen I, Coelmont L, et al. Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors. Antimicrob Agents Chemother 2008; 52: 3433-7.
20. Vliegen I, Paeshuyse J, De Burghgraeve T, et al. Substituted imidazopyridines as potent inhibitors of HCV replication. J Hepatol 2009; 50: 999-1009.
21. Delang L, Paeshuyse J, Vliegen I, et al. Statins potentiate the in vitro anti-hepatitis C virus activity of selective hepatitis C virus inhibitors and delay or prevent resistance development. Hepatology 2009; 50: 6-16.
22. Delgrange D, Pillez A, Castelain S, et al. Robust production of infectious viral particles in Huh-7 cells by introducing mutations in hepatitis C virus structural proteins. J Gen Virol 2007; 88: 2495-503.
23. Zhong J, Gastaminza P, Chung J, et al. Persistent hepatitis C virus infection in vitro: coevolution of virus and host. J Virol 2006; 80: 11082-93.
24. Prichard MN, Shipman C Jr. Analysis of combinations of antiviral drugs and design of effective multidrug therapies. Antivir Ther 1996; 1: 9-20.
25. Paeshuyse J, Kaul A, De CE, et al. The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro. Hepatology 2006; 43: 761-70.
26. Walsh CT. Vancomycin resistance: decoding the molecular logic. Science 1993; 261: 308-9.
27. Malabarba A, Ciabatti R. Glycopeptide derivatives. Curr Med Chem 2001; 8: 1759-73.
28. Zhanel GG, Calic D, Schweizer F, et al. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin. Drugs 2010; 70: 859-86.
29. Boger DL. Vancomycin, teicoplanin, and ramoplanin: synthetic and mechanistic studies. Med Res Rev 2001; 21: 356-81.
30. Anderson KE, Eliot LA, Stevenson BR, et al. Formulation and evaluation of a folic acid receptor-targeted oral vancomycin liposomal dosage form. Pharm Res 2001; 18: 316-22.
31. Birk AV, Dubovi EJ, Zhang X, et al. Antiviral activity of geneticin against bovine viral diarrhoea virus. Antivir Chem Chemother 2008; 19: 33-40.
32. Zhang XG, Mason PW, Dubovi EJ, et al. Antiviral activity of geneticin against dengue virus. Antiviral Res 2009; 83: 21-7.
33. Van BF, Saffran J, Mingeot-Leclercq MP, et al. Mixed-lipid storage disorder induced in macrophages and fibroblasts by oritavancin (LY333328), a new glycopeptide antibiotic with exceptional cellular accumulation. Antimicrob Agents Chemother 2005; 49: 1695-700.
34. Domenech O, Francius G, Tulkens PM, et al. Interactions of oritavancin, a new lipoglycopeptide derived from vancomycin, with phospholipid bilayers: effect on membrane permeability and nanoscale lipid membrane organization. Biochim Biophys Acta 2009; 1788: 1832-40.
35. Syed GH, Amako Y, Siddiqui A. Hepatitis C virus hijacks host lipid metabolism. Trends Endocrinol Metab 2010; 21: 33-40.
36. Moradpour D, Gosert R, Egger D, et al. Membrane association of hepatitis C virus nonstructural proteins and identification of the membrane alteration that harbors the viral replication complex. Antiviral Res 2003; 60: 103-9.
37. McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360: 1827-38.